The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:2590-2591 December 14, 2006 Number 24
NextNext

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Olaussen, K. A.
To the Editor: Olaussen and colleagues (Sept. 7 issue)1 report a survival benefit associated with the absence of the excision repair cross-complementation group 1 (ERCC1) protein in patients with completely resected non–small-cell lung cancer who received adjuvant cisplatin-based chemotherapy. Most of the operative specimens of ERCC1-positive tumors examined were squamous-cell carcinoma, whereas the ERCC1-negative tumors were almost evenly divided between squamous-cell carcinoma and adenocarcinoma.1 Does this skewed distribution reflect a selection bias?

Originally, the International Adjuvant Lung Cancer Trial (IALT) showed a difference in survival of 2.3 percentage points for patients with squamous-cell tumors who received cisplatin (as compared with . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.